Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
accepted:
19
03
2023
medline:
4
4
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Tirbanibulin 1% ointment is a new treatment for actinic keratosis (AK) on the face or scalp. A health economic model was developed as part of a submission to the Scottish Medicines Consortium to evaluate the cost-effectiveness of tirbanibulin compared to the most frequently prescribed treatments. A decision tree approach was used to calculate the costs and benefits of different treatment strategies for AK on the face or scalp over a one-year time horizon. Data on the relative efficacy of treatments, which were based on the probability of complete clearance of AK, were obtained from a network meta-analysis. Sensitivity and scenario analyses were performed to determine the robustness of the model results. Tirbanibulin is estimated to be cost saving versus diclofenac sodium 3%, imiquimod 5% and fluorouracil 5%. Tirbanibulin remains cost saving when inputs are varied in sensitivity and scenario analyses. While the complete clearance rates are deemed similar across comparators, tirbanibulin is associated with a lower rate of severe local skin reactions, and a shorter treatment duration, which may improve treatment adherence. Tirbanibulin is a cost saving intervention for the treatment of AK from the perspective of the Scottish Healthcare System.
Sections du résumé
BACKGROUND
BACKGROUND
Tirbanibulin 1% ointment is a new treatment for actinic keratosis (AK) on the face or scalp. A health economic model was developed as part of a submission to the Scottish Medicines Consortium to evaluate the cost-effectiveness of tirbanibulin compared to the most frequently prescribed treatments.
METHODS
METHODS
A decision tree approach was used to calculate the costs and benefits of different treatment strategies for AK on the face or scalp over a one-year time horizon. Data on the relative efficacy of treatments, which were based on the probability of complete clearance of AK, were obtained from a network meta-analysis. Sensitivity and scenario analyses were performed to determine the robustness of the model results.
RESULTS
RESULTS
Tirbanibulin is estimated to be cost saving versus diclofenac sodium 3%, imiquimod 5% and fluorouracil 5%. Tirbanibulin remains cost saving when inputs are varied in sensitivity and scenario analyses. While the complete clearance rates are deemed similar across comparators, tirbanibulin is associated with a lower rate of severe local skin reactions, and a shorter treatment duration, which may improve treatment adherence.
CONCLUSIONS
CONCLUSIONS
Tirbanibulin is a cost saving intervention for the treatment of AK from the perspective of the Scottish Healthcare System.
Identifiants
pubmed: 37012513
doi: 10.1007/s41669-023-00410-5
pii: 10.1007/s41669-023-00410-5
pmc: PMC10170011
doi:
Types de publication
Journal Article
Langues
eng
Pagination
443-454Informations de copyright
© 2023. The Author(s).
Références
Cochrane Database Syst Rev. 2012 Dec 12;12:CD004415
pubmed: 23235610
Br J Dermatol. 2007 Dec;157 Suppl 2:34-40
pubmed: 18067630
J Clin Med. 2022 Mar 16;11(6):
pubmed: 35329979
Br J Dermatol. 2011 Nov;165(5):1101-8
pubmed: 21517801
J Med Econ. 2017 Mar;20(3):221-227
pubmed: 27715356
Arch Dermatol. 1991 Jul;127(7):1029-31
pubmed: 2064402
J Am Acad Dermatol. 2010 Apr;62(4):582-90
pubmed: 20133013
Pharmacoeconomics. 2010;28(11):1055-64
pubmed: 20936887
N Engl J Med. 2021 Feb 11;384(6):512-520
pubmed: 33567191
J Investig Dermatol Symp Proc. 2004 Mar;9(2):160-8
pubmed: 15083784
N Engl J Med. 2019 Mar 7;380(10):935-946
pubmed: 30855743
Br J Dermatol. 2006 Oct;155(4):784-90
pubmed: 16965429
Br J Dermatol. 2017 Jan;176(1):20-43
pubmed: 28098380
J Eur Acad Dermatol Venereol. 2012 Jan;26(1):48-53
pubmed: 21414035
Eur J Health Econ. 2016 Apr;17(3):287-304
pubmed: 25795391